106th Day Of Lockdown

Maharashtra2237241231929448 Tamil Nadu118594711161636 Delhi102831742173165 Gujarat37636267441978 Uttar Pradesh2996819627313 Telangana2761216287313 Karnataka2681511100417 West Bengal2383715790804 Rajasthan2140416575472 Andhra Pradesh211979745252 Haryana1799913645279 Madhya Pradesh1562711768622 Bihar12525933898 Assam12523833016 Odisha10097670354 Jammu and Kashmir89315399143 Punjab67494554175 Kerala5895345228 Chhatisgarh3415272814 Uttarakhand3230262143 Jharkhand3018210422 Goa190311568 Tripura171612481 Manipur14307710 Himachal Pradesh107876410 Puducherry104351714 Nagaland6443030 Chandigarh4924017 Arunachal Pradesh270922 Mizoram1971390 Sikkim125650 Meghalaya94432
Business Companies 03 Jun 2020 India's drug re ...

India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir

PTI
Published Jun 3, 2020, 11:53 am IST
Updated Jun 3, 2020, 4:08 pm IST
The approval process for remdesivir was accelerated in view of emergency situation and unmet need for medicines in light of covid19 outbreak
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir. (AFP Photo)
 India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir. (AFP Photo)

New Delhi: Anti-viral drug remdesivir has been approved for "restricted emergency use" on severe COVID-19 patients in view of the crisis posed by the pandemic, the Union health ministry said on Tuesday.

Joint Secretary in the ministry Lav Agarwal said the permission for remdesivir was given following due process based on the available evidence.

 

India's drug regulator granted US pharma giant Gilead Sciences the marketing authorisation for its drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, sources said.

The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak, a source in the know of the developments told PTI.

The drug has been allowed for restricted emergency use for a maximum five-day period for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said.

"The drug, which is administered in the form of an injection, has been approved to be sold by retail on the prescription of specialists for use in a hospital or institutional set-up only. It has been approved for use for a maximum of five days as against 10 days. Extended use does not seem to have any beneficial effects, based on the evidence submitted at the time of approval.

"The approval process for remdesivir was accelerated by invoking special provisions under the New Drug and Clinical Trial Rules, 2019, which provide for a waiver of clinical trials in special circumstances," the source told PTI.

Gilead Sciences had, on May 29, applied for the marketing authorisation for remdesivir in India. The drug is being touted as a potential treatment method for COVID-19.

The approval was given following consultation with the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO).

"The drug is given in the form of an injection and that is why it has to be administered under the supervision of a doctor in a hospital setting," the source said.

The drug would be imported by Mumbai-based Klinera Global Services from Gilead's manufacturing site, the source added.

Gilead Sciences, the patent-holder of the drug, has the complete data of the pre-clinical and clinical studies for remdesivir.

The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for the treatment of hospitalised patients with severe COVID-19.

Meanwhile, applications of two Indian pharmaceutical companies -- Cipla and Hetero Labs -- seeking permission to manufacture and sell remdesivir in India are under consideration.

Gilead Sciences Inc. has entered into non-exclusive licensing agreements with pharma firms, including three domestic majors Cipla, Jubilant Life Sciences and Hetero, for the manufacture and distribution of remdesivir.

The Indian Council of Medical Research (ICMR) had earlier said anti-viral medication remdesivir, which was used during the Ebola outbreak, may inhibit the SARS-CoV-2 replication and the research on its efficacy in the treatment of COVID-19 is a part of the WHO's "Solidarity Trial".

...
Location: India, Delhi, New Delhi




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT